Cover Image


Global Heparin Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 254966
出版日期 內容資訊 英文 73 Pages
Back to Top
肝素的全球市場:2016∼2020年 Global Heparin Market 2016-2020
出版日期: 2016年03月17日 內容資訊: 英文 73 Pages

肝素是由嗜鹼性球及肥胖細胞產生的抗凝血劑。對已形成的血栓無作用,不過能溶化體內的血栓。還有也可從豬腸和牛肺提取、製造成藥品,從外部取得。肝素根據分級的程度,分為UFH、LMWH、ULMWH3個種類,按照症狀分開使用。全球肝素市場,預共2016∼2020年為4.74%的年複合成長率 (CAGR) 。


第1章 摘要整理

  • 調查結果的概要

第2章 調查範圍

  • 調查概要
  • 大供應商的主要產品

第3章 市場分析技術

  • 分析方法
  • 經濟指標

第4章 簡介

  • 市場趨勢的概要
  • 主要的購買標準

第5章 肝素:概要

  • 作用機制 (MOA)
  • 肝素使用的限制
  • 在肝素臨床的使用
  • 品牌藥簡介

第6章 開發中產品的組合

  • LMW肝素MMX
  • URG101
  • 肝素
  • 肝素及脫氧核糖核酸酶 (DNAse)
  • 肝素及其他的吸入藥

第7章 市場環境

  • 全球血液凝固阻止藥的市場
  • 全球肝素市場
  • 波特的五力分析

第8章 在肝素的CPB手術的使用

  • CPB (心肺體外循環)
  • 在肝素的CPB手術的使用
  • CPB手術用肝素的全球市場

第9章 肝素API (原料藥) 的市場

  • 中國:肝素API的市場

第10章 粗肝素的供應商

  • FDA的供應商用指南

第11章 各類型產品的市場區隔

  • UFH (未分級肝素)
  • LMWH (低分子量肝素)
  • ULMWH (超低分子量肝素)

第12章 給藥途徑 (ROA) 各的市場區隔

  • 靜脈內 (IV) 注射/注入
  • 皮下 (SC) 注射

第13章 地區區分

  • 全球肝素市場:各地區的詳細趨勢 (今後6年份)
  • 歐洲、中東、非洲各國 (EMEA) 市場
  • 南北美洲市場
  • 亞太地區市場

第14章 市場成長的促進要素

  • 相關疾病的患病人數的增加
  • 粗肝素的供應鏈的擴大
  • 美國FDA (食品藥物管理局) 再引進牛肝素

第15章 促進要素與其影響

第16章 市場課題

  • 隨著專利到期,集中利用非專利產品
  • 副作用的風險
  • 粗肝素的不足
  • 低劣品的威脅
  • 已經普及口服抗凝血劑的存在

第17章 促進要素與課題的影響

第18章 市場趨勢

  • 新的治療用途的開拓預測
  • 策略性聯盟
  • 研究開發 (R&D) 的活躍
  • 新的肝素解毒劑的上市

第19章 供應商環境

  • 競爭模式
  • 市場分析
  • Sanofi
  • Pfizer
  • Aspen
  • LEO Pharma
  • 其他卓越供應商

第20章 附錄

  • 簡稱清單

第21章 關於Technavio



Product Code: IRTNTR9053

About Heparin

Heparin, a disaccharide anticoagulant or blood thinner, prevents the formation of blood clots. It is produced in the body by basophils and mast cells. It is stored within mast cells and secreted at the injury site. Though it has no effect on already formed clots, it enables the body's natural clot lysis mechanisms to dissolve clots. It can also be taken from outside as a drug. Heparin can be derived from natural sources such as pig intestine and bovine lungs.

Heparin is divided into two types based on the fractionation process. Both types have medical use, with the selection done based on preference for a particular condition.

UFH: It is directly obtained from natural sources, without undergoing any fractionation.

LMWH: It is derived by depolymerizing UFH. The pharmacodynamics properties of LMWH are more predictable when compared to UFH.

Apart from these, another category of molecules, ULMWH are available. They are structurally related to LMWHs, but differ in the composition of monosaccharides and oligosaccharides. Therefore, they have different average molecular weights from LMWH.

Technavio's analysts forecast the global heparin market to grow at a CAGR of 4.74% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global heparin market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generics used to treat disorders.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Heparin Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • GlaxoSmithKline plc (GSK)
  • Leo Pharma A/S
  • Pfizer Inc.
  • Sanofi

Other Prominent Vendors

  • Alchemi
  • Baxter
  • BMS
  • Boehringer Ingelheim
  • Celgene
  • Cosmo Pharmaceuticals
  • Dr.Reddy's Laboratories
  • Eisai
  • Fresenius
  • GSK
  • Hospira
  • Laboratorios Rovi Pharmaceuticals
  • Lee's Pharmaceutical
  • Momenta Pharmaceuticals
  • Mylan
  • Novartis
  • Ockham Biotech
  • Perospher
  • PolyMedix
  • Portola Pharmaceutical
  • ProStrakan Group
  • Sagent Pharmaceticals
  • Sigma Tau Pharmaceuticals
  • UCB
  • Urigen Pharmaceuticals

Market driver

  • Growing prevalence of diseases
  • For a full, detailed list, view our report

Market challenge

  • Extensive use of generic products due to patent expirations
  • For a full, detailed list, view our report

Market trend

  • Expected exploitation of new therapeutic use
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Key buying criteria

PART 05: Heparin: An overview

  • Mechanism of action (MOA)
  • Limitations of heparin use
  • Clinical uses of heparin
  • Branded drug profiles

PART 06: Pipeline portfolio

  • LMW Heparin MMX
  • URG101
  • Heparin
  • Heparin plus dexoyribonuclease (DNAse)
  • Heparin plus other inhaled drug

PART 07: Market landscape

  • Global anticoagulant drugs market
  • Global heparin market
  • Five forces analysis

PART 08: Heparin use in CPB surgery

  • CPB
  • Heparin use in CPB surgery
  • Global heparin market in CPB surgeries

PART 09: Heparin API market

  • China: Heparin API market

PART 10: Suppliers of crude heparin

  • FDA guidance for heparin suppliers
  • PART 11: Market segmentation by product type
  • UFH
  • LMWH

PART 12: Market segmentation by ROA

  • IV injection/infusion
  • SC injection

PART 13: Geographical segmentation

  • Global heparin market by geographical segmentation 2015-2020
  • Heparin market in EMEA
  • Heparin market in Americas
  • Heparin market in APAC

PART 14: Market drivers

  • Growing prevalence of diseases
  • Increase in supply chains of crude heparin
  • Reintroduction of bovine heparin by US FDA

PART 15: Impact of drivers

PART 16: Market challenges

  • Extensive use of generic products due to patent expirations
  • Risk of side-effects
  • Shortage of crude heparin
  • Threat of adulteration
  • Presence of well-established oral anticoagulants

PART 17: Impact of drivers and challenges

PART 18: Market trends

  • Expected exploitation of new therapeutic use
  • Strategic alliances
  • Increase in R&D
  • Entry of new heparin antidotes

PART 19: Vendor landscape

  • Competitive scenario
  • Market analysis 2015
  • Sanofi
  • Pfizer
  • Aspen
  • LEO Pharma
  • Other prominent vendors

PART 20: Appendix

  • List of abbreviations

PART 21: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Key buying criteria for heparin drugs
  • Exhibit 03: Differences between porcine heparin and bovine heparin
  • Exhibit 04: Process of blood coagulation
  • Exhibit 05: Mechanism of action of heparin
  • Exhibit 06: Pipeline portfolio: Heparin drugs
  • Exhibit 07: Market share of global heparin market in global anticoagulant drugs market 2015
  • Exhibit 08: Global anticoagulant drugs market 2015-2020 ($ billions)
  • Exhibit 09: Global heparin market 2015-2020 ($ billions)
  • Exhibit 10: Five forces analysis
  • Exhibit 11: Global heparin market in CPB surgeries 2015-2020 ($ millions)
  • Exhibit 12: Process of crude heparin production in China
  • Exhibit 13: Segmentation of global heparin market by product type 2015
  • Exhibit 14: Segmentation of global heparin market by ROA
  • Exhibit 15: Segmentation of global heparin market based on geography 2015
  • Exhibit 16: Global heparin market revenue by geography 2015-2020 ($ billions)
  • Exhibit 17: Global heparin market by geography 2015-2020
  • Exhibit 18: Heparin market in EMEA 2015-2020 ($ billions)
  • Exhibit 19: Heparin market in Americas 2015-2020 ($ billions)
  • Exhibit 20: Heparin market in APAC 2015-2020 ($ billions)
  • Exhibit 21: Global heparin market: YoY growth and revenue based on geography 2015-2020
  • Exhibit 22: Impact of drivers
  • Exhibit 23: Impact of drivers and challenges
  • Exhibit 24: Sanofi: YoY revenue and growth rate of Lovenox 2013-2015 ($ billions)
  • Exhibit 25: Geographical segmentation of Lovenox 2015
  • Exhibit 26: Sanofi: Key takeaways
  • Exhibit 27: Pfizer: YoY revenue and growth rate of Fragmin 2013-2015 ($ millions)
  • Exhibit 28: Geographical segmentation of Fragmin by revenue 2015
  • Exhibit 29: Pfizer: Key takeaways
  • Exhibit 30: Aspen: Key takeaways
  • Exhibit 31: LEO Pharma: Key takeaways
Back to Top